Log In
Print
BCIQ
Print
Print this Print this
 

Rifamycin SV MMX (CB-01-11)

  Manage Alerts
Collapse Summary General Information
Company Cosmo Pharmaceuticals S.p.A.
DescriptionBroad-spectrum, semisynthetic, oral non-absorbable antibiotic formulated with MMX multi-matrix system technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPhase III
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD); Treat travelers' diarrhea
Regulatory Designation

Partner

Dr. Falk Pharma GmbH


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today